Veru (VERU) announced that it has commenced an underwritten public offering of shares of its common stock and accompanying Series A warrants and Series B warrants to purchase shares of its common stock. All securities to be sold in the proposed public offering will be offered by Veru. Veru intends to use the net proceeds from the proposed offering to fund the development of enobosarm, with a primary focus on Phase 2b PLATEAU clinical study activities. Some of the proceeds will also be used for working capital purposes, including existing vendor obligations, and for other general corporate purposes including working with potential development partners for enobosarm. Canaccord Genuity and Oppenheimer & Co. are acting as joint book-running managers for the offering.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VERU:
- Veru Inc. Completes Promising Phase 2 Study on Enobosarm for Weight Management
- Veru Settles Debt with Onconetix Agreement
- Onconetix announces financing through private placement, debt settlement
- Veru announces FDA meeting providing regulatory clarity for Enobosarm
- Veru Inc’s Earnings Call: Clinical Success Amid Financial Struggles